Tony Frugier

Tony Frugier

Auto-generated profile, based on publicly available information

Tony Frugier

University of Melbourne

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in Journal of Neurotrauma
Verified
Journal Article
Closed access
TFTony Frugier
Tony Frugier
MMMaria Cristina Morganti-Kossmann
Maria Cristina Morganti-Kossmann
DODavid O'REilly
David O'REilly
CMCatriona A. McLean
Catriona A. McLean
Little is known about the molecular events following severe traumatic brain injury (TBI) in humans and to date there are no efficient therapies for the treatment of patients. In this study, the first of its kind in human tissue, a total of 21 post mortem trauma brain samples were analyzed. The inflammatory response within the brain tissue was explored by measuring the expression of various inflammatory cytokines at the mRNA and protein levels. These mediators were interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and granulocyte-macrophage colony-stimulating factor (GM-CSF). This study shows for the first time in human brain tissue that 1) pro-inflammatory mediator protein levels are significantly increased in situ following acute brain injury while anti-inflammatory cytokines protein levels remain unchanged; 2) the cerebral inflammatory response begins within minutes of acute TBI, much earlier than previously thought; 3) IL-6, IL-8, TNF-α, and IL-1β mRNA levels are significantly increased following injury; 4) the rise in cytokine protein level coincides with increased levels of their mRNAs suggesting that traumatic injury elicits an immediate cerebral inflammatory response. Altogether these data confirm and extend previous observations on the release of cytokines in the cerebrospinal fluid of severe TBI patients. Finally, this study highlights the need to characterize the cell source of cytokines and elucidate their mode of action.

1 October 1999 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
PMPierre Miniou
Pierre Miniou
DTDanilo Tiziano
Danilo Tiziano
TFTony Frugier
Tony Frugier
NRNatacha Roblot
Natacha Roblot
MMMarianne Le Meur
Marianne Le Meur
JMJudith Melki
Judith Melki
Spatially and temporally regulated somatic mutations can be achieved by using the Cre/LoxP recombination system of bacteriophage P1. In order to develop gene knockouts restricted to striated muscle, we generated a transgenic mouse line expressing Cre recombinase under the control of the human α-skeletal actin promoter. Specific excision of a loxP-flanked gene was demonstrated in striated muscle, heart and skeletal muscle, in a pattern very similar to the expression of the endogenous α-skeletal actin gene. Therefore, the reported transgenic line can be used to target inactivation or activation of a given gene to the skeletal muscle lineage.

1 June 2002 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
CDCarmen Cifuentes Diaz
Carmen Cifuentes Diaz
SNSophie Nicole
Sophie Nicole
MVMaria E Velasco
Maria E Velasco
CBChristophe Borra-Cebrian
Christophe Borra-Cebrian
CPCristina Panozzo
Cristina Panozzo
JMJudith Melki
Judith Melki
Retinitis pigmentosa (RP) and allied diseases are heterogeneous clinically and genetically. Here we summarize the retinal cell types involved in these diseases, the large number of genes that cause them, and the variety of inheritance patterns that the affected families display. Special consideration is given to unusual inheritance patterns. The aggregate carrier frequency for recessive RP alleles may be as high as 10%.

22 March 2000 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
TFTony Frugier
Tony Frugier
FTFrancesco D. Tiziano
Francesco D. Tiziano
CDCarmen Cifuentes Diaz
Carmen Cifuentes Diaz
PMPierre Miniou
Pierre Miniou
NRNatacha Roblot
Natacha Roblot
JMJudith Melki
Judith Melki
Deletion of the murine survival of motor neuron gene (SMN) exon 7, the most frequent mutation found in spinal muscular atrophy (SMA) patients, directed to neurons but not to skeletal muscle, enabled generation of a mouse model of SMA providing evidence that motor neurons are the primary target of the gene defect. Moreover, the mutated SMN protein (SMNΔC15) is dramatically reduced in the motor neuron nuclei and causes a lack of gems associated with large aggregates of coilin, a coiled-body-specific protein. These results identify the lack of the nuclear targeting of SMN as the biochemical defect in SMA.

5 March 2001 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
CDCarmen Cifuentes Diaz
Carmen Cifuentes Diaz
TFTony Frugier
Tony Frugier
FTFrancesco D. Tiziano
Francesco D. Tiziano
ELEmmanuelle Lacène
Emmanuelle Lacène
NRNatacha Roblot
Natacha Roblot
JMJudith Melki
Judith Melki
Spinal muscular atrophy (SMA) is characterized by degeneration of motor neurons of the spinal cord associated with muscle paralysis and caused by mutations of the survival motor neuron gene (SMN). To determine whether SMN gene defect in skeletal muscle might have a role in SMA pathogenesis, deletion of murine SMN exon 7, the most frequent mutation found in SMA, has been restricted to skeletal muscle by using the Cre-loxP system. Mutant mice display ongoing muscle necrosis with a dystrophic phenotype leading to muscle paralysis and death. The dystrophic phenotype is associated with elevated levels of creatine kinase activity, Evans blue dye uptake into muscle fibers, reduced amount of dystrophin and upregulation of utrophin expression suggesting a destabilization of the sarcolemma components. The mutant mice will be a valuable model for elucidating the underlying mechanism. Moreover, our results suggest a primary involvement of skeletal muscle in human SMA, which may contribute to motor defect in addition to muscle denervation caused by the motor neuron degeneration. These data may have important implications for the development of therapeutic strategies in SMA.

5 April 2017 in Brain
Verified
Journal Article
Open access
PDF file
Blaine RobertsBlaine Roberts
Blaine Roberts
MLMonica Lind
Monica Lind
AWAaron Z. Wagen
Aaron Z. Wagen
ARAlan Rembach
Alan Rembach
TFTony Frugier
Tony Frugier
CMColin L. Masters
Colin L. Masters
We fractionated frontal cortical grey matter from human Alzheimer’s disease and control subjects into four biochemically defined pools that represent four distinct compartments: soluble/cytosolic, peripheral membrane/vesicular cargo, integral lipid/membranous pools and aggregated/insoluble debris. Most of the readily extractable amyloid-β remains associated with a lipid/membranous compartment. There is an exchange of amyloid-β between the biochemical pools that was lost for the amyloid-β42 species in Alzheimer’s disease, consistent with the peptide being irreversibly trapped in extracellular deposits. The quantitative amyloid-β data, combined with magnetic resonance imaging volumetric analysis of the amount of cortical grey matter in brain, allowed us to estimate the total mass of amyloid-β in Alzheimer’s disease (6.5 mg) and control (1.7 mg) brains. The threshold positron emission tomography standard uptake value ratio of 1.4 equates to 5.0 μg amyloid-β/g of grey matter and the mean Alzheimer’s disease dementia standard uptake value ratio level of 2.3 equates to 11.20 μg amyloid-β/g of grey matter. It takes 19 years to accumulate amyloid from the threshold positron emission tomography standard uptake value ratio to the mean value observed for Alzheimer’s disease dementia. This accumulation time window combined with the difference of 4.8 mg of amyloid-β between Alzheimer’s disease and control brain allows for a first approximation of amyloid-β accumulation of 28 ng/h. This equates to an estimated 2–5% of the total amyloid-β production being deposited as insoluble plaques. Understanding these rates of amyloid-β accumulation allows for a more quantitative approach in targeting the failure of amyloid-β clearance in sporadic Alzheimer’s disease.